Company: LBRX
Filing Date: 2025-09-08
Form Type: S-1/A
Source: 0001193125-25-197877
Chunk: 116

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-09-08
Form: S-1/A
Chunk 116
---
-compliance with the listing requirements of Nasdaq.

72

Our quarterly and annual operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts or any guidance we may publicly provide, each of which may cause our stock price to fluctuate or decline. We expect our operating results to be subject to quarterly and annual fluctuations which may, in turn, cause the price of our common stock to fluctuate substantially. Our net loss and other operating results will be affected by numerous factors, including:

| • |     | variations in the level of expense related to the ongoing development of 
 LB-102 or future development programs;                                   |

| • |     | results and timing of preclinical studies and ongoing and future clinical trials, or the addition or termination 
 of any such clinical trials;                                                                                     |

| • |     | the timing of payments we may make or receive under existing license and collaboration arrangements or the 
 termination or modification thereof;                                                                       |

| • |     | our execution of any strategic transactions, including acquisitions, collaborations, licenses, or similar        
 arrangements, and the timing and amount of payments we may make or receive in connection with such transactions; |

| • |     | any intellectual property infringement lawsuit or opposition, interference, or cancellation proceeding in which 
 we may become involved;                                                                                         |

| • |     | recruitment and departures of key personnel; |

| • |     | if our product candidate receives regulatory approval in the future, the terms of such approval, and market 
 acceptance and demand for such products;                                                                    |

| • |     | regulatory developments affecting our product candidate or those of our competitors; |

| • |     | global or regional public health emergencies, including any health epidemics and their residual effects, natural 
 disasters, or major catastrophic events;                                                                         |

| • |     | adverse macroeconomic conditions or geopolitical events, including the conflict between Ukraine and Russia, the 
 conflict between Israel and Hamas, high levels of inflation, heightened interest rates, and bank failures;      |

| • |     | the impacts of inflation and rising interest rates on our business and operations; and |

| • |     | changes in general market and economic conditions. |

If our quarterly or annual operating results fall below the expectations of investors or securities analysts or any forecasts or guidance we may provide to the market, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated guidance we may provide. We believe that quarterly or annual comparisons of our